fjrigjwwe9r0Board:Content
THE IMPACT OF ESSENTIAL FATTY ACIDS
ON THE AGING PROCESS (11)
Rashid Buttar, D. O. and Andrew Halpner, Ph. D.
Utilizing specific combinations of EFAs with other carrier substances, these new polypeptide treatment modalities now have a way of being delivered into the system in a trans-dermal manner without the concerns of denaturing or issues regarding compliance. Furthermore, not only do these EFA trans-dermal transport delivery mechanisms allow for convenient dosing, but are reported to actually contribute to stabilizing the polypeptide structures. Not surprisingly, assimilation into the system is also achieved beyond that of other delivery mechanisms including other non-EFA trans-dermal delivery mechanisms.
Final thoughts
The therapeutic potential of EFAs in all fields of medicine has been definitively established. For example, we now recognize that enzyme deficiencies, such as those observed with D-6-desaturase, decrease the synthesis of n-6 and n-3 PUFAs. In addition, these enzyme deficiencies may be particularly important in the actual process of aging, where D-6-desaturase activity is already impaired.
We need to learn how EFAs can be advanced beyond simple supplementation, and utilized in therapeutic modalities. New discoveries about EFAs promise to advance the field of longevity medicine, not only by increasing the life span of our future generations, but by improving the quality of that increased life.
References
1) Adams PB, Lawson S, Sanigorski A, et al: Arachidonic to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31: S167-S176, 1996.
2) Anderson GJ, Connor WE: Accretion of n-3 fatty acids in the brain and retina of chick fed a low linolenic acid diet supplemented with docosahexaenoic acid. Am J Clin Nutr 59: 1338-1346, 1994.
3) Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 38: 151-160, 1995.
4) Belch JJF, Ansell D, Madhok R, et al: Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheuma-toid arthritis: a double-blind, placebo-controlled study. Ann Rheum Dis 47: 96-104, 1988.
5) Belch JJF, Hill A: Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 71( suppl): 352S-356S, 2000.
6) Biran LA, Bartley W, Carter CW, Renshaw A: Studies on essential fatty acid defi-ciency: effect of the deficiency on the lipids in various rat tissues and the influence of dietary supplementation with essential fatty acids on deficient rats. Biochem J 93: 492-498, 1964.
7) Bland JS: Nutritional Improvement of Health Outcomes: The Inflammatory Disorders. Gig Harbor: HealthComm, Inc., 1997, pp. 109-161.
8) Blok WL, Katan MB, van der Meer JW: Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. Journal of Nutrition 126: 1515 -1533, 1996.
9) Bordoni A, Hrelia S, Lorenzini A, Bergami R, Cabrini L, Biagi PL, Tolomelli B: Dual influence of aging and vitamin B6 deficiency on delta-6 desaturation of essential fatty acids in rat liver microsomes. Prostaglandins Leukot Essent Fatty Acids 58: 417-42, 1998.
10) Borland VG, Jackson CM: (name of article?) Arch Pathol 11: 687-708, 1931.
11) Bourre JM, Dumont OS, Piciotti MJ, et al: Dietary alpha-linolenic acid deficiency in adult rats for 7 months does not alter brain docosahexaenoic acid content in contrast to liver heart and testes. Biochim Biophys Acta 1124: 119-122, 1992.
12) Buck AC, Lote CJ, Sampson WF: The influence of renal prostaglandins on urinary calcium excretion in idiopathic urolithiasis. J Urol 129: 421-426, 1983.
13) Buck AC, Smellie WS, Jenkins A, et al. In: Ryall R (ed): Urolithiasis 2. New York: Plenum Press, 1994, pp. 575-580.
14) Burr G O, Piciotti M, Dumont O: A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 82: 345-367, 1929.
15) Buttar RA, Viktora DC, Quinn ME: Accelerated and efficacious results using variable somatrotroph specific polypeptide combinants as an alternative to oral growth hormone: secretagogues and synthetic human growth hormone injections. Neuroendocrinology Letters, Submitted.
16) Calissi PT, Jaber LA: Peripheral diabetic neuropathy: current concepts and treatment. Annals of Pharmacotherapy 29: 769-777, 1995.
17) Carroll KK, Davidson MB: The role of lipids in tumorigenesis. In: Molecular Interrelations of Nutrition and Cancer. New York: Raven Press, 1982, pp. 237 -245.
18) Cohen BM, Zubenko GS: Aging and the biophysical properties of cell membranes. Life Sci 37: 1403-1409, 1985.
19) Das UN: Essential fatty acids and osteoporosis [editorial]. Nutrition 16: 386-390, 2000.
< |